Stromal fibroblasts in cancer initiation and progression

Nature

Volumn 432, Issue 7015, 2004, Pages 332-337

  Bhowmick, Neil A ^a,b   Neilson, Eric G ^a,b   Moses, Harold L ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; CARCINOGENS; CELLS;

CARCINOMAS; FIBROBLASTS; MUTATIONS;

TUMORS;

FIBROBLAST GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

CANCER;

CANCER GROWTH; CARCINOGENESIS; CELL TYPE; DNA MODIFICATION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; GROWTH INHIBITION; HUMAN; HUMAN CELL; INFLAMMATORY CELL; MICROENVIRONMENT; MOLECULAR RECOGNITION; PARACRINE SIGNALING; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; STROMA CELL; TISSUE SPECIFICITY; VASCULARIZATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FIBROBLASTS; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 9244227134     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03096     Document Type: Review

References (67)

1. Lengauer, C., Kinzler, K. W. & Vogelstein, B. Genetic instabilities in human cancers. Nature 396, 643-649 (1998).
2. Ronnov-Jessen, L., Petersen, O. W. & Bissell, M. J. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol. Rev. 76, 69-125 (1996).
3. Tlsty, T. D. & Hein, P. W. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. 11, 54-59 (2001).
4. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
5. Sandler, A. B., Johnson, D. H. & Herbst, R. S. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin. Cancer Res. 10, 4258s-4262s (2004).
6. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
7. Weaver, V. M. et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231-245 (1997).
8. Ronnov-Jessen, L., Petersen, O. W., Koteliansky, V. E. & Bissell, M. J. The origin of the myofibroblasts in breast cancer. Recapitulation of tumour environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J. Clin. Invest. 95, 859-873 (1995).
9. Kalluri, R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nature Rev. Cancer 3, 422-433 (2003).
10. Cunha, G. R., Reese, B. A. & Sekkingstad, M. Induction of nuclear androgen-binding sites in epithelium of the embryonic urinary bladder by mesenchyme of the urogenital sinus of embryonic mice. Endocrinology 107, 1767-1770 (1980).
11. Xin, L., Ide, H., Kim, Y., Dubey, P. & Witte, O. N. In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. Proc. Natl Acad. Sci. USA 100(suppl. 1), 11896-11903 (2003).
12. Cunha, G. R., Bigsby, R. M., Cooke, P. S. & Sugimura, Y. Stromal-epithelial interactions in adult organs. Cell Differ. 17, 137-148 (1985).
13. Culig, Z. et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 28, 392-405 (1996).
14. Cunha, G. R. & Donjacour, A. A. Mesenchymal-epithelial interactions in the growth and development of the prostate. Cancer Treat Res. 46, 159-75 (1989).
15. Hayward, S. W. Approaches to modeling stromal-epithelial interactions. J. Urol. 168, 1165-1172 (2002).
16. Hayward, S. W. & Cunha, G. R. The prostate: development and physiology. Radiol. Clin. North Am. 38, 1-14 (2000).
17. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nature Med. 10, 789-799 (2004).
18. Dawe, C. J. in Tissue Interactions in Carcinogenesis. (ed. Tarin, D.) 305-358 (Academic, London, 1972).
19. Schor, S. L., Schor, A. M. & Rushton, G. Fibroblasts from cancer patients display a mixture of both foetal and adult-like phenotypic characteristics. J. Cell Sci. 90, 401-407 (1988).
20. Schor, S. L., Schor, A. M., Rushton, G. & Smith, L. Adult, foetal and transformed fibroblasts display different migratory phenotypes on collagen gels: evidence for an isoformic transition during foetal development J. Cell Sci. 73, 221-234 (1985).
21. Russell, P. J., Bennett, S. & Stricker, P. Growth factor involvement in progression of prostate cancer. Clin. Chem. 44, 705-723 (1998).
22. Olumi, A. F. et al. Carcinoma-associated fibroblasts direct tumour progression of initiated human prostatic epithelium. Cancer Res. 59, 5002-11 (1999).
23. Hayward, S. W. et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 61, 8135-8142 (2001).
24. Barcellos-Hoff, M. H. & Ravani, S. A. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60, 1254-1260 (2000).
25. Ohuchida, K. et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumour-stromal interactions. Cancer Res. 64, 3215-3222 (2004).
26. Krtolica, A., Parrinello, S., Lockett, S., Desprez, P. Y. & Campisi, J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA 98, 12072-12077 (2001).
27. Allinen, M. et al. Molecular characterization of the tumour microenvironment in breast cancer. Cancer Cell 6, 17-32 (2004).
28. Tucker, R. F., Shipley, G. D., Moses, H. L. & Holley, R. W. Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science 226, 705-777 (1984).
29. Moses, H. L. et al. Type β transforming growth factor is a growth stimulator and a growth inhibitor. Cancer Cells 3, 65-71 (1985).
30. Pierce, D. F. Jr et al. Mammary tumour suppression by transforming growth factor beta 1 transgene expression. Proc. Natl Acad. Sci. USA 92, 4254-4258 (1995).
31. Bottinger, E. P., Jakubczak, J. L., Haines, D. C., Bagnall, K. & Wakefield, L. M. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7, 12-dimethylbenz-[a]- anthracene. Cancer Res. 57, 5564-5570 (1997).
32. Gorska, A. E. et al. Transgenic mice expressing a dominant-negative mutant type II TGF-β receptor have impaired mammary development and enhanced mammary tumour formation. Am. J. Pathol. 163, 1539-1549 (2003).
33. Amendt, C., Schirmacher, P., Weber, H. & Blessing, M. Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 17, 25-34 (1998).
34. Akhurst, R. J. & Derynck, R. TGF-beta signalling in cancer-a double-edged sword. Trends Cell Biol. 11, S44-S51 (2001).
35. Gold, L. I. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit. Rev. Oncog. 10, 303-360 (1999).
36. Tsushima, H. et al. Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin. Cancer Res. 7, 1258-1262 (2001).
37. Shariat, S. F. et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J. Clin. Oncol. 19, 2856-2864 (2001).
38. Shariat, S. F. et al. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer 92, 2985-2992 (2001).
39. Bhowmick, N. A. et al. TGF-beta signalling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848-851 (2004).
40. Kuperwasser, C. et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA 101, 4966-4971 (2004).
41. Nakamura, T., Matsumoto, K., Kiritoshi, A. & Tano, Y. Induction of hepatocyte growth factor in fibroblasts by tumour-derived factors affects invasive growth of tumour cells: in vitro analysis of tumour-stromal interactions. Cancer Res. 57, 3305-3313 (1997).
42. Birchmeier, C., Birchmeier, W., Gherardi, E. & Vande Woude, G. F. Met, metastasis, motility and more. Nature Rev. Mol. Cell Biol. 4, 915-925 (2003).
43. Michieli, P. et al. Targeting the tumour and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6, 61-73 (2004).
44. Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361 (2003).
45. Massague, J., Blain, S. W. & Lo, R. S. TGF-beta signalling in growth control, cancer, and heritable disorders. Cell 103, 295-309 (2000).
46. Koskinen, P. J., Sistonen, L., Bravo, R. & Alitalo, K. Immediate early gene responses of NIH 3T3 fibroblasts and NMuMG epithelial cells to TGF beta-1. Growth Factors 5, 283-293 (1991).
47. Lynch, C. C. & Matrisian, L. M. Matrix metalloproteinases in tumour-host cell communication. Differentiation 70, 561-573 (2002).
48. Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 161-174 (2002).
49. Itoh, T. et al. Reduced angiogenesis and tumour progression in gelatinase A-deficient mice. Cancer Res. 58, 1048-1051 (1998).
50. Brauchle, M., Angermeyer, K., Hubner, G. & Werner, S. Large induction of keratinocyte growth factor expression by serum growth factors and pro-inflammatory cytokines in cultured fibroblasts. Oncogene 9, 3199-3204 (1994).
51. Yan, G., Fukabori, Y., Nikolaropoulos, S., Wang, F. & McKeehan, W. L. Heparin-binding keratinocyte growth factor is a candidate stromal-to- epithelial-cell andromedin. Mol. Endocrinol. 6, 2123-2128 (1992).
52. Lu, W., Luo, Y., Kan, M. & McKeehan, W. L. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J. Biol. Chem. 274, 12827-12834 (1999).
53. Jin, C. et al. Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumours. Cancer Res. 64, 4555-4562 (2004).
54. Furuhashi, M. et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumours and an associated increase in tumour growth rate. Cancer Res. 64, 2725-2733 (2004).
55. Jue, S. F., Bradley, R. S., Rudnicki, J. A., Varmus, H. E. & Brown, A. M. The mouse Wnt-1 gene can act via a paracrine mechanism in transformation of mammary epithelial cells. Mol. Cell. Biol. 12, 321-328 (1992).
56. Derksen, P. W. et al. Illegitimate WNT signalling promotes proliferation of multiple myeloma cells. Proc. Natl Acad. Sci. USA 101, 6122-6127 (2004).
57. Marnett, L. J., Riggins, J. N. & West, J. D. Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J. Clin. Invest. 111, 583-593 (2003).
58. Moinfar, F. et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res. 60, 2562-2566 (2000).
59. Kurose, K. et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nature Genet. 32, 355-357 (2002).
60. Xue, C., Plieth, D., Venkov, C., Xu, C. & Neilson, E. G. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res. 63, 3386-3394 (2003).
61. Jacoby, R. F. et al. A juvenile polyposis tumour suppressor locus at 10q22 is deleted from nonepithelial cells in the lamina propria. Gastroenterology 112, 1398-1403 (1997).
62. Wirtzfeld, D. A., Petrelli, N. J. & Rodriguez-Bigas, M. A. Hamartomatous polyposis syndromes: molecular genetics, neoplastic risk, and surveillance recommendations. Ann. Surg. Oncol. 8, 319-327 (2001).
63. Waite, K. A. & Eng, C. From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. Nature Rev. Genet. 4, 763-773 (2003).
64. Yang, Y. A. et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109, 1607-1615 (2002).
65. Trusolino, L. & Comoglio, P. M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature Rev. Cancer 2, 289-300 (2002).
66. Wessells, N. K. Mammalian lung development: interactions in formation and morphogenesis of tracheal buds. J. Exp. Zool. 175, 455-466 (1970).
67. Bellusci, S. et al. Involvement of Sonic hedgehog (Shh) in mouse embryonic lung growth and morphogenesis. Development 124, 53-63 (1997).